Company intelligence / Profile preview
Inhibikase Therapeutics, Inc.
Atlanta, Georgia, United Statesinhibikase.com ↗
- Ownership
- Public · IKT
- Development stage
- Other
01
Overview
Currently advancing IkT-001Pro into Phase 2b '702' trial for Pulmonary Arterial Hypertension (PAH). Previously discontinued risvodetinib (IkT-148009) for Parkinson's disease in January 2025 after Phase II trial showed safety but failed to demonstrate significant efficacy in primary endpoints.
- Therapeutic areas
- GastroenterologyCardiovascularNeurology
- Modalities
- Small moleculesProtein kinase inhibitorsAbelson Tyrosine Kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Financials
- Market cap
- $200.9M
- Total revenue
- $0
- Enterprise value
- $41.9M
Beyond the preview
Go deeper on Inhibikase Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibikase Therapeutics, Inc..